|
|
|
|
LEADER |
00000nam a22000005i 4500 |
001 |
978-3-319-08982-9 |
003 |
DE-He213 |
005 |
20220114113546.0 |
007 |
cr nn 008mamaa |
008 |
160607s2016 sz | s |||| 0|eng d |
020 |
|
|
|a 9783319089829
|9 978-3-319-08982-9
|
024 |
7 |
|
|a 10.1007/978-3-319-08982-9
|2 doi
|
050 |
|
4 |
|a RC1-1245
|
072 |
|
7 |
|a MJC
|2 bicssc
|
072 |
|
7 |
|a MED027000
|2 bisacsh
|
072 |
|
7 |
|a MJC
|2 thema
|
082 |
0 |
4 |
|a 616
|2 23
|
245 |
1 |
0 |
|a Handbook of Incretin-based Therapies in Type 2 Diabetes
|h [electronic resource] /
|c edited by Stephen Gough.
|
250 |
|
|
|a 1st ed. 2016.
|
264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Adis,
|c 2016.
|
300 |
|
|
|a IX, 92 p. 20 illus., 16 illus. in color.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
505 |
0 |
|
|a Introduction and disease overview -- Incretin hormones as a target for therapy -- Glucagon-like peptide receptor agonists -- Dipeptidyl peptidase-4 inhibitors -- Global position and recommendations for use -- Future and emerging therapies. .
|
520 |
|
|
|a .
|
650 |
|
0 |
|a Diseases.
|
650 |
1 |
4 |
|a Diseases.
|
700 |
1 |
|
|a Gough, Stephen.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer Nature eBook
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319089812
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319089836
|
856 |
4 |
0 |
|u https://doi.uam.elogim.com/10.1007/978-3-319-08982-9
|z Texto Completo
|
912 |
|
|
|a ZDB-2-SME
|
912 |
|
|
|a ZDB-2-SXM
|
950 |
|
|
|a Medicine (SpringerNature-11650)
|
950 |
|
|
|a Medicine (R0) (SpringerNature-43714)
|